Skip to search formSkip to main contentSkip to account menu

Zubrod Performance Status

Known as: Zubrod, Zubrod Score, Zubrod Score Performance Status 
A scale used to assess how a patient's disease is progressing and assess how the disease affects the daily living abilities of the patient.
National Institutes of Health

Related topics

Related topics

1 relation
ECOG performance status

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2019
Highly Cited
2019
The Development of Chronic Critical Illness Determines Physical Function, Quality of Life, and Long-Term Survival Among Early Survivors of Sepsis in Surgical ICUs*
Objectives: This study sought to examine mortality, health-related quality of life, and physical function among sepsis survivors… 
Highly Cited
2015
Highly Cited
2015
Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of Radiation Therapy Oncology Group 0424.
Highly Cited
2013
Highly Cited
2013
Pilot study of comprehensive geriatric assessment (CGA) in allogeneic transplant: CGA captures a high prevalence of vulnerabilities in older transplant recipients.
Highly Cited
2012
Highly Cited
2012
A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma: preliminary results of RTOG 0417…
Highly Cited
2008
Highly Cited
2008
Predictors of prolonged length of stay after lobectomy for lung cancer: a Society of Thoracic Surgeons General Thoracic Surgery Database risk-adjustment model.
Highly Cited
2001
Highly Cited
2001
Phase I trial of oral green tea extract in adult patients with solid tumors.
PURPOSE This trial was designed to determine the maximum-tolerated dose, toxicity, and pharmacology of oral green tea extract… 
Highly Cited
1997
Highly Cited
1997
Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer.
BACKGROUND This randomised study was designed to determine the response rate survival and toxicity of single-agent gemcitabine… 
Highly Cited
1996
Highly Cited
1996
Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma.
PURPOSE To determine the efficacy and toxicity of topotecan administered as a 5-day intravenous infusion in patients with… 
Highly Cited
1995
Highly Cited
1995
Survival predictors in advanced non-small cell lung cancer.
Review
1972
Review
1972
Combination cancer therapy: Presidential address.
TheUniversityofTexas,M.D.AndersonHospitalandTumorinstitute,TexasMedicalCenter,Houston… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)